Immetacyte   Report issue

For profit Phase 2
Founded: Manchester United Kingdom (2008)
Status: Left NME R&D (2005)

Organization Overview

First Clinical Trial
2008
NCT00446836
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Immetacyte Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 6